Thousands of pages of documents have recently been unsealed in court in a lawsuit filed by a former Celgene saleswoman.
The suit alleges that Thalomid's success is due to an aggressive campaign by Celgene to encourage doctors to prescribe the drug for off-label indications.
Even after the FDA approved Thalomid for multiple myeloma in the mid-2000s, Celgene continued to promote it for other forms of cancer, including cervix, thyroid and brain, whistleblower Beverly Brown says in the suit, filed in 2010.
Brown's case has moved forward in California, with the unsealing of thousands of pages of new documents and emails that Brown's attorneys think back up their client’s claims.
Read the Bloomberg press release